⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Obstructive sleep apnea (OSA) is one of India's most underdiagnosed serious conditions. Estimates suggest that **13–26% of Indian adults** may have clinically significant OSA — a condition where the throat muscles relax during sleep, blocking the airway and causing repeated episodes of stopped or shallow breathing throughout the night.
The link between OSA and obesity is well-established, and India's rapidly rising rates of central obesity (particularly high waist-to-hip ratios even at lower BMIs) mean that many GLP-1 users are managing both conditions simultaneously.
In 2024, a major clinical trial (SURMOUNT-OSA) showed that tirzepatide (Mounjaro) reduced apnea-hypopnea index (AHI) events by up to **63% in participants not using CPAP** — the most significant improvement ever seen with a pharmaceutical intervention for OSA. Earlier data from semaglutide trials also showed meaningful improvement in sleep-disordered breathing.
This guide explains what Indian patients with sleep apnea need to know about GLP-1 therapy.
**Consult your healthcare provider before starting any medication.** This article is informational only and does not constitute medical advice.
OSA occurs when the muscles at the back of the throat — including the tongue, soft palate, and uvula — relax during sleep and block airflow. The brain registers the drop in oxygen and briefly wakes the person to restore breathing. This can happen **5 to 100+ times per hour** in severe cases.
The consequences extend far beyond poor sleep:
Despite its prevalence, OSA is dramatically underdiagnosed in India for several reasons:
1. **Sleep studies (polysomnography) are expensive** — ₹8,000–₹25,000 for a full study; home sleep tests now available at ₹3,000–₹8,000
2. **Snoring is normalised** — many Indian families consider loud snoring unremarkable, even in children
3. **Low awareness among general practitioners** — OSA is often not screened for during routine consultations
4. **Stigma around CPAP machines** — the treatment (Continuous Positive Airway Pressure) involves wearing a mask at night, which many patients find embarrassing
If you snore loudly, wake up with headaches, feel exhausted despite sleeping 7–8 hours, or your bed partner has noticed you stop breathing during sleep, ask your doctor about a sleep study.
India has unique risk patterns for OSA that differ from Western populations:
GLP-1 medications improve OSA through two main mechanisms:
The primary mechanism is straightforward: losing weight, particularly fat around the neck, jaw, and tongue, reduces the physical obstruction that causes apnea events. Clinical trials consistently show that a **10% reduction in body weight leads to approximately a 25–35% reduction in AHI events**.
GLP-1 medications typically produce weight loss of 10–22% of body weight over 1–2 years, which translates to meaningful OSA improvement in most patients.
Research published in *Lancet Respiratory Medicine* suggests that GLP-1 receptors exist in the brainstem regions that control breathing. Semaglutide and tirzepatide may improve the brain's respiratory drive during sleep — independent of weight loss alone. In some SURMOUNT-OSA participants, AHI improvement was greater than what weight loss alone would predict.
The landmark SURMOUNT-OSA trial (2024, published in *New England Journal of Medicine*) enrolled 469 participants with moderate-to-severe OSA and obesity — half using CPAP and half not using CPAP.
Key findings:
| Outcome | Tirzepatide group | Placebo group |
|---|---|---|
| AHI reduction (non-CPAP users) | 63% reduction | 6% reduction |
| AHI reduction (CPAP users) | 51% reduction | 5% reduction |
| Body weight reduction | 18.1% | 0.7% |
| Systolic blood pressure | -9 mmHg | -2 mmHg |
| Proportion achieving remission (AHI <5) | ~51% | ~13% |
**What does this mean for Indian patients?** For those with obesity-related OSA — which describes the majority of OSA patients in India — tirzepatide (Mounjaro) represents a genuinely transformative treatment option, not just for weight, but specifically for sleep apnea severity.
Similar but smaller-magnitude improvements have been shown with semaglutide (Ozempic/Wegovy) in related trials.
Before starting GLP-1 therapy, ask your doctor for a referral for a home sleep test or full polysomnography. This gives you a baseline AHI score to compare against as you lose weight. A **sleep study is available at most major hospitals in India** (Apollo, Fortis, AIIMS, PGI Chandigarh, and dedicated sleep clinics).
Do not stop your CPAP machine because you are now on GLP-1. Continue CPAP until your doctor reassesses your sleep study. As your weight decreases, your required CPAP pressure may need adjustment — this requires your sleep physician to re-evaluate.
Neck circumference is a simple proxy for OSA risk. For Indians, a neck circumference above **38 cm in women or 43 cm in men** is associated with significantly higher OSA risk. Tracking this monthly can help you and your doctor gauge improvement.
After 3–6 months on GLP-1 with significant weight loss, ask your doctor about a repeat sleep study. Your AHI may have improved enough to:
Weight loss and medication help OSA — but good sleep habits accelerate improvement:
See a sleep physician (pulmonologist, neurologist, or ENT with sleep training) if:
| Type | Cost Range | Where Available |
|---|---|---|
| Home sleep test (Type 3 device) | ₹3,000–₹8,000 | Apollo, Fortis, Medanta, dedicated sleep clinics |
| Full polysomnography (Type 1) | ₹8,000–₹25,000 | Major hospitals with sleep labs |
| CPAP machine (purchase) | ₹15,000–₹50,000 | Phillips, ResMed, and local medical suppliers |
| CPAP rental | ₹2,000–₹5,000/month | Available through sleep clinics |
Home sleep tests are now widely available and are sufficient to diagnose most cases of moderate-to-severe OSA. They do not require an overnight hospital stay.
**Q: I have been on Mounjaro for 4 months and I am sleeping much better. Can I stop CPAP?**
Improved sleep quality is encouraging but is not a reliable indicator that your OSA has reached safe levels. Please ask your doctor for a repeat sleep study before making any changes to CPAP use.
**Q: My doctor has not mentioned OSA even though I snore loudly and am obese. Should I bring it up?**
Yes, absolutely. OSA is significantly underdiagnosed in India. Tell your doctor you snore loudly, feel unrefreshed after sleep, and have obesity or central adiposity. Request a screening questionnaire (STOP-Bang is a validated tool) and a sleep study if the screen is positive.
**Q: Is Mounjaro (tirzepatide) available in India for sleep apnea specifically?**
As of 2026, tirzepatide (Mounjaro) is available in India through prescription for type 2 diabetes and obesity. Its sleep apnea indication is based on the SURMOUNT-OSA trial. Discuss with your doctor whether tirzepatide is appropriate for your combined obesity-OSA profile.
**Q: Can semaglutide (Ozempic/Wegovy) also help sleep apnea?**
Yes — semaglutide-related weight loss improves OSA in proportion to weight lost. While the SURMOUNT-OSA data specifically involves tirzepatide, semaglutide studies have also shown AHI improvement, primarily attributable to weight loss.
